The main purpose of this study is to assess the effect of carbamazepine on the amount of orforglipron in the bloodstream and how long it takes the body to get rid of orforglipron when given orally in healthy study participants. The safety and tolerability of orforglipron and carbamazepine when given separately or together will also be evaluated. The study may last up to approximately 77 days for each participant.

开始日期2024-05-03

申办/合作机构

Eli Lilly & Co.

CTR20234303 / Recruiting临床3期

在二甲双胍治疗后血糖控制不佳的2型糖尿病成人受试者中评价每日一次口服orforglipron与达格列净相比的有效性和安全性的3期,随机,开放标签研究（ACHIEVE-2）

证实orforglipron 3 mg、12 mg和/或36 mg在血糖控制方面非劣效于达格列净

开始日期2024-01-29

申办/合作机构

Lilly del Caribe, Inc.

[+2]

CTR20240093 / Recruiting临床3期

在使用甘精胰岛素单用或联合二甲双胍和/或SGLT-2抑制剂后血糖控制不佳的2型糖尿病成人受试者中评价每日一次口服orforglipron与安慰剂相比的有效性和安全性的3期、随机、双盲研究（ACHIEVE-5）

本研究旨在确定在甘精胰岛单用或联合二甲双胍和/或 SGLT-2 抑制剂治疗基础上，评估orforglipron与安慰剂相比的获益和风险。本研究将评价3种orforglipron剂量（3mg、12mg和36mg）与安慰剂相比的降糖作用。此外，本研究将比较orforglipron与安慰剂对体重和总体安全性特征的作用。

开始日期2024-01-29

申办/合作机构

Lilly del Caribe, Inc.

[+2]

100 项与 Orforglipron 相关的临床结果

登录后查看更多信息

100 项与 Orforglipron 相关的转化医学

登录后查看更多信息

100 项与 Orforglipron 相关的专利（医药）

登录后查看更多信息

项与 Orforglipron 相关的文献（医药）

2024-02-24·Diabetes therapy : research, treatment and education of diabetes and related disorders

Effect of Food Consumption on the Pharmacokinetics, Safety, and Tolerability of Once-Daily Orally Administered Orforglipron (LY3502970), a Non-peptide GLP-1 Receptor Agonist.

Article

作者: Xiaosu Ma ; Rong Liu ; Edward J Pratt ; Charles T Benson ; Shobha N Bhattachar ; Kyle W Sloop

INTRODUCTION:

We assessed the effect of the prandial state on the pharmacokinetics, safety, and tolerability of single and multiple doses of orforglipron (LY3502970), an oral, non-peptide glucagon-like peptide 1 receptor agonist (GLP-1 RA), in two studies (A and B).

METHODS:

Study A and study B were phase 1, randomized, crossover studies in healthy adults aged 18-65 years and 21-70 years, respectively. Participants received single (3 mg, study A) or multiple (16 mg, study B) oral doses of orforglipron under fasted and fed conditions. Blood samples were collected pre- and postdose to assess area under the concentration-time curve (AUC), maximum observed drug concentration (C_max), time of C_max (t_max), and half-life (t_1/2) associated with terminal rate constant. AUC and C_max were analyzed using a linear mixed-effects model. Treatment differences were presented as ratios of geometric least squares means (GLSM). Treatment-emergent adverse events (TEAEs), adverse events of special interest, and serious adverse events were assessed.

RESULTS:

Study A included 12 participants (mean age 45.0 years; male 66.7%); study B included 34 participants (mean age 42.8 years; male 88.2%). GLSM AUC and C_max were lower by 23.7% and 23.2% in study A, and 17.6% and 20.9% in study B, in the fed versus fasted states, respectively. In both studies, t_1/2 and median t_max were comparable between fed and fasted states. The majority of TEAEs in both studies were gastrointestinal tract-related conditions. No serious adverse events or deaths were reported in either study.

CONCLUSION:

The observed pharmacokinetic differences due to the prandial state are unlikely to contribute to clinically meaningful differences in the efficacy of orforglipron. The safety profile was consistent with the known profiles of other GLP-1 RAs. Given the absence of prandial restrictions, orforglipron may emerge as a convenient oral treatment option for patients with type 2 diabetes or obesity.

TRIAL REGISTRATION:

ClinicalTrials.gov identifiers, NCT03929744 and NCT05110794.

2024-01-23·Current diabetes reviews

Future is Brighter: New Potential Paradigm-Shifting Medications and Regimens for Diabetes and Obesity.

Article

作者: Rami A Al-Horani ; Kholoud F Aliter ; Hashem F Aliter

Diabetes is a chronic illness that can become debilitating owing to its microvascular and macrovascular complications. Its prevalence is increasing and so is its cost. Diabetes, particularly type 2, appears to have a very close relationship with obesity. While lifestyle modifications, exercises, and current therapeutics have substantially improved clinical outcomes, the need for new therapeutics and regimens continue to exist. Several new medications and regimens for diabetes, obesity, and diabesity are showing promising results in advanced clinical trials. For type 1 diabetes mellitus (T1DM), they include teplizumab, ustekinumab, jakinibs, and cell therapies, whereas for type 2 diabetes mellitus (T2DM), they include once-weakly insulin, tirzepatide, high oral dose of semaglutide, orforglipron, retatrutide, CagriSema, and survodutide. Given their structural and mechanistic diversity as well as their substantial efficacy and safety profiles, these medications and regimens are paradigm shifting and promise a brighter future. They will likely enable better disease prevention and management. This review will provide details about each of the above strategies to keep the scientific community up to date about progress in the fields of diabetes and obesity.

2024-01-18·Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Efficacy and safety of GLP-1RAs for people with obesity: A systematic review based on RCT and Bayesian network meta-analysis.

Review

作者: Hong Li ; Guanzheng Yu ; Qi Huang ; Bao Yang ; Juan Nie ; Yinbei Liu ; Xing Tu

BACKGROUND:

GLP-1 receptor agonists (GLP-1RAs) reduce glucagon and glycogen secretion, inhibit appetite and slow gastric empties and have recently been approved to treat obesity.

OBJECTIVE:

To explore the safety and efficacy of GLP-1RAs in the treatment of obesity and clarify the optimal GLP-1RAs treatment regimen.

METHODS:

PubMed, Embase, Web of Science, and Cochrane Library databases were searched for English randomized controlled trials (RCTs) on GLP-1RAs in the treatment and management of obesity published before July 18, 2023. Literature screening and data extraction were performed independently by three researchers. Bayesian random effect model was used to compare the effects of interventions. Continuous variables were expressed as mean difference with 95% CI, and dichotomous variables were reported as RR with 95% CI.

RESULTS:

A total of 29 studies with 10,333 participants were included in the present study. The combination of cagrilintide and semaglutide (short for cagrANDsema) was an optimal strategy for weight loss and glycosylated hemoglobin (HbA1c) reduction. Compared to placebo, cagrANDsema reduced weight by - 14.13 kg (95% CI: -16.49, -11.73) and HbA1c by - 0.33% (95% CI: -0.41, -0.25). Moreover, this study indicated that orforglipron and semaglutide also had relatively good effects on weight loss. Meta-regression results indicated that higher dose levels might have better effects on weight loss.

CONCLUSIONS:

CagrANDsema exerts the best effect for weight loss. In terms of current dose levels, a higher dose gets better weight-loss effects without increasing the risk of adverse events.

183

项与 Orforglipron 相关的新闻（医药）

2024-04-08

·GBIHealth

年度收藏：跨国药企核心产品管线布局、研发进度-2023 H2（上篇）

引文跨国药企掌握着全球医药行业最强大的网络资源和决策智慧，他们用真金白银投票选择的方向有更大概率是较符合技术进步规律的（当然这既不意味着他们的决策一定正确、也不意味着这些决策能够被有效执行），通过对他们所有核心产品管线进行系统梳理并定期更新，就有助于我们系统性地了解在大药企自己的话语体系里，究竟哪些方向是在做的、有进展的、值得期待的，从而可以对判断到底什么是所谓“主流技术方向”有更全面直观的依据。本篇将为大家梳理礼来、诺和诺德、强生、默沙东、艾伯维五家企业的管线情况。在GLP-1横扫一切的强势驱动下，无论是业绩和市值，还是各自的产品布局，全球大药企都在经历深刻的变局，甚至可以说进行了颠覆性的重排，仅是下面这张摘要图与半年前相比就有不小的差异。- 左右滑动查看更多 -Lilly礼来礼来在2023年一骑绝尘成功登顶全球药企市值之冠，更夸张的是在2024年刚过两个月又从5,000多亿飚到7,000多亿，眼看就要冲着人类有史以来第一个万亿市值药企的壮举而去了。不过，这疯狂的市值还是有大幅预支未来成长之嫌，毕竟过往业绩虽然表现不俗，但也绝不是成倍的爆发式增长，且看未来是“预支”还是“透支”了。当然，礼来的业绩成长本身确实非常震撼，Tirzepatide在第一个完整销售年度豪取53亿美元、其中Q4单季24亿，在这种震古烁今的爬坡速度驱动下，礼来整体收入额一举从2022年的285亿跃升到2023年的341亿，而且仍处在继续向上跃升的过程中，2024年的业绩指引就是收入提升到410亿左右。- 左右滑动查看更多 -管线的攻城略地仍在发力：在万众瞩目的减肥线上，Tirzepatide肥胖适应症终于获批、并公布了MASH二期临床topline数据，Retatrutide和Orforglipron的多个三期临床先后启动；自免线上，Mirikizumab终于获批、并公布了CD三期临床结果，而Lebrikizumab却收到了FDA的CRL；Donanemab上市却意外地再次被推迟；肿瘤线上，Pirtobrutinib获批CLL/SLL适应症，从POINT收购来的核药PNT-2002也加入管线。- 左右滑动查看更多 -NOVO NORDISK诺和诺德诺和诺德在这波GLP-1狂潮中，市值从1,000亿飙升到接近6,000亿，与礼来呈一时瑜亮之势，在公司创立百年之际达到了可以说是从未有过的高度。看诺和诺德这十年以来的业绩成长，也确实配得上市值的提升。Semaglutide的三个品牌合计在2023年带来了近220亿美元销售额，不过近几个季度在GLP-1中的处方量市场份额已经开始走平，Tirzepatide迅速爬坡带来的竞争压力肉眼可见。- 左右滑动查看更多 -产能制约依然是严重瓶颈，特别是从2023年5月之后低剂量的供应出现明显的受限、以至于对国际市场还会实施供应量限制，从2024年1月开始逐渐增加供应能力，比起半年报时候“will remain restricted”的表述来看应该是有所缓解；产能扩建则继续加码，连续三年持续Capex翻倍的计划。- 左右滑动查看更多 -最重要的研发进展当然还属Semaglutide获批用于心血管风险保护、公布慢性肾病和HFpEF等三期临床结果，以及刚刚公布Amycretin一期的惊艳减重数据；其他值得关注的进展包括高草酸尿症RNAi疗法Nedosiran终于获批，Icosema完成三期临床，从中国药企KBP收购高血压资产等；瘦身也在持续，两个罕见病疗法Belcesiran和Eclipse先后消失在管线中。- 左右滑动查看更多 -J&J强生强生虽然业绩持续稳定，但市值近期下滑到4,000亿以下，被礼来与诺和诺德连续超车。强生医药板块的业绩在大药企中还是相当稳健，其中Ustekinumab和Daratumumab两大引擎的驱动力都非常充足，Guselkumab和Macitentan+Selexipag也表现不俗，但Ibrutinib、Infliximab、Abiraterone、Paliperidone等曾经的超重磅品种确实老态渐显。研发方面最突出的依然是在多发性骨髓瘤领域的“遮断性”优势，不过近期高歌猛进似有放缓，主要进展包括：Talquetamab获得欧盟批准；Teclistamab两周一次剂型获批；Daratumumab皮下剂型公布一线可移植MM患者的三期临床数据；Cilta-cel二线MM适应症获得欧盟积极意见；BCMA/CD3/GPRC5D三抗JNJ-5322公布一期临床数据。其他值得关注的进展包括：2019年从Taris收购来的新型膀胱内药物输送系统TAR-200/201分别公布了二期和一期数据；FcRn单抗Nipocalimab公布二期RA数据并获得FDA突破性认证；FGFR抑制剂Erdafitinib获得FDA完全批准并公布三期临床THOR2研究结果。管线新陈代谢正在进行，从收购Ambrx获得ARX-517/788等ADC资产，而RPGR AAV从管线中被拿掉。- 左右滑动查看更多 -MSD默沙东默沙东近期收入端依然表现稳健，K药仍在增长并稳住了药王地位（虽然刚上位没多久），HPV疫苗也增速不减，这两大定海神针填上了Molnupiravir急速缩水以及Sitagliptin专利悬崖带来的缺口，市值还是逼近3,000亿。研发进展中依然一大半都还是围绕K药的各种扩适应症和联用方案，近期主要进展包括：围手术期NSCLC的三期OS结果；获批1L HER2阴性胃癌和胆管癌等适应症；与mRNA-4157合作启动NSCLC辅助治疗的三期临床。其他重点值得关注的包括：与第一三共达成重大合作获得多个ADC管线，其中U3-1402已提交上市申请；HIF2α抑制剂Belzutifan获批2L RCC适应症；TIGIT单抗Vibostolimab公布与K药联用的NSCLC二期数据；肺炎疫苗V116和PAH药物Sotatercept提交上市申请；从科伦引进的TROP2 ADC、BTK C481S抑制剂Nemtabrutinib、CYP11A1抑制剂和LSD1抑制剂MK-5684Bomedemstat等启动三期临床。此外，收购Harpoon获得的DLL3/CD3/Albumin三抗加入管线，而P2X3慢性咳嗽药物Gefapixant则再次收到CRL。- 左右滑动查看更多 -Abbvie艾伯维2023年以来，Adalimumab和Ibrutinib两大超重磅受竞争者的挤压销售额开始出现大幅下滑，所幸Risankizuma、Upadacitinib、Venetoclax、Cariprazine几个新生代贡献一定的增量，整体业绩才算没有太崩坏，因此市值基本上还是稳定在2,500亿上下。眼看着业绩支撑轴在发生更迭，艾伯维将Risankizumab和Upadacitinib的峰值预期提高到170亿和100亿以上，试图再造一个Adalimumab时代的免疫帝国。- 左右滑动查看更多 -管线方面同样是在经历重心的迁移：免疫线逐渐收缩到围绕现有重磅的适应症扩展，近期包括Risankizumab公布与Ustekinumab在CD适应症的头对头三期临床结果、Upadacitinib公布白癜风二期临床结果，此外IL-1α/β双抗Lutikizumab公布化脓性汗腺炎二期临床结果，另有SCF248、IL-2、GLP-2等新机制加入管线；肿瘤线进展包括收购Immunogen并获得多个ADC资产，CD20×CD3双抗Epcoritamab获得欧盟批准并向FDA提交末线FL的上市申请，Teliso-V公布NSCLC二期临床数据，同时补充了大批新项目进入管线；神经/精神线进展较多，帕金森复方药物ABBV-951提交上市申请，偏头痛药物Atogepant和Ubrogepant分别提交预防适应症的上市申请和公布前兆适应症的三期临床数据，此外通过87亿巨额收购Cerevel补充多个AD/PD管线。- 左右滑动查看更多 -数据声明本文选取截至2023年12月31日市值超过1,000亿美元的制药企业，共11家。已上市产品包括收入贡献较大的（年销售额10亿美元以上）、尚在增长或稳定期的（获批10年以上的基本不考虑）和仍在积极开发阶段的（正在进行重要适应症扩展的临床试验）；临床在研管线以年报季报的研发进度更新章节、研发日及重要会议展示材料和公司日常信息披露等取并集，故可以理解为公司自己认为当前优先级较高的管线，而并不覆盖全体管线。主要梳理信息包括近几个季度的市值和收入利润变化（多主业公司只取制药板块）、半年内最重要的审批进展和临床数据发布、以及未来近期的重要里程碑。\ | /★联系我们投稿 | 发稿 | 媒体合作▶ sylvia.hua@generalbiologic.com数据库 | 咨询服务 | 资讯追踪▶ 点击左下“阅读原文”完成表单填写点击阅读原文订阅全球行业新闻

临床3期并购

2024-04-03

·BioSpace

Four Doses of Lilly’s Mounjaro Will Be in Short Supply Through April 2024: FDA

Pictured: Eli Lilly's world headquarters in Indianapolis/iStock, jetcityimage Multiple doses of Eli Lilly’s top-selling diabetes medication Mounjaro (tirzepatide) will be in short supply through April 2024, according to the FDA’s database for drug shortages and discontinuations. Mounjaro’s 7.5-mg, 10-mg, 12.5-mg and 15-mg dose strengths will have limited availability throughout the month, according to the FDA. The shortage is due to a spike in the demand for the diabetes therapy. The availability of Mounjaro’s lower dose levels—5-mg and 2.5-mg—will not be impacted. The regulator’s update on the Mounjaro shortage follows a previous notice by the FDA in February 2024, in which it announced that the three highest dose levels of the medication would be in short supply. According to reporting by Reuters, Lilly at the time expected that it would need until early March 2024 to address back orders for the 10-mg, 12.5-mg and 15-mg doses of Mounjaro. A Lilly spokesperson in a statement to Fierce Pharma pointed to the “unprecedented demand” for Mounjaro as the reason for the shortage, adding that the company is “moving with purpose and urgency to ensure our innovations are available to those who need them.” Mounjaro’s active ingredient is tirzepatide, a GLP-1 receptor agonist that mimics the GLP-1 hormone to induce the secretion of insulin from the pancreas in response to blood sugar level. Mounjaro is indicated for the treatment of type 2 diabetes, for which it won approval in May 2022. However, it has been used on an off-label basis for chronic weight management. In November 2023, the FDA formally approved tirzepatide for the treatment of obesity, for which it carries the brand name Zepbound. Currently, Lilly shares the lucrative obesity market with Novo Nordisk whose GLP-1 receptor agonist semaglutide is also indicated for type 2 diabetes as Ozempic, and for weight management as Wegovy. Analysts expect the two companies to capture the vast majority of the obesity space, which in the coming years could reach up to $200 billion in value. Both Lilly and Novo have struggled to keep up with the market’s insatiable appetite for obesity treatments. To bolster its supply capacity, Lilly in November 2023 invested $2.5 billion to build a manufacturing facility in Germany, focusing on the production of its diabetes and obesity products. The plant will allow Lilly to hire an additional 1,000 skilled workers, such as engineers, operators and scientists. Construction for this facility is scheduled to begin this year. Lilly also revealed in its fourth-quarter 2023 earnings report in February 2024 that it was making additional investments in its manufacturing capacity to prepare for the company’s next-generation oral weight-loss therapy orforglipron. Novo has worked to improve its semaglutide supply with the $16.5 billion acquisition of CDMO giant Catalent, a $6 billion boost to its manufacturing capacity in Denmark and a $556 million contract to expand its sterile preparations operations in China. Tristan Manalac is an independent science writer based in Metro Manila, Philippines. Reach out to him on LinkedIn or email him at tristan@tristanmanalac.com or tristan.manalac@biospace.com.

并购上市批准

2024-04-01

·药时代

司美格鲁肽生物类似药，如何开展临床试验？

2024年4月1日，CDE发布《司美格鲁肽注射液生物类似药体重管理适应症临床试验设计指导原则（征求意见稿）》。本指导原则自2023年11月启动并形成初稿。2023年12月7日召开了司美格鲁肽注射液生物类似药体重管理适应症临床试验设计扩大的沟通会，邀请企业代表以及临床专家、统计与临床药理专家参会，经过充分讨论基本达成共识。基于扩大沟通会的意见，对初稿进行了修订。通过部门讨论，中心内部征求意见，技术委员会审核，形成了征求意见稿。据不完全统计，华东医药、联邦制药、丽珠医药、石药集团、正大天晴等多家药企已将司美格鲁肽注射液生物类似药推至临床三期。相关专利布局方面，原研司美格鲁肽的化合物中国专利将于2026年3月到期，不过该专利已于2022年9月被国家专利局宣告无效，而诺和诺德也已针对该决定向北京知识产权法院提出了上诉。惠升生物也曾于2022年4月就诺和诺德司美格鲁肽的专利递交无效申请。此外，对与研发热点的跟随，司美格鲁肽口服版、替尔泊肽都值得关注。2023年6月，司美格鲁肽注射液在国内的上市申请获药监局受理；2023年8月，替尔泊肽注射液减重适应症的注册申请获国家药监局受理；2023年10月，礼来Orforglipron（口服GLP-1）启动国内三期临床试验 ACHIEVE-1，针对二型糖尿病。以下为《司美格鲁肽注射液生物类似药体重管理适应症临床试验设计指导原则（征求意见稿）》详情。封面图来源：CDE官网版权声明/免责声明本文为汇编文章。本文仅作信息交流之目的，不提供任何商用、医用、投资用建议。文中图片、视频、字体、音乐等素材或为药时代购买的授权正版作品，或来自微信公共图片库，或取自公司官网/网络，部分素材根据CC0协议使用，版权归拥有者，药时代尽力注明来源。如有任何问题，请与我们联系。衷心感谢!药时代官方网站:www.drugtimes.cn联系方式:电话:13651980212微信:27674131邮箱:contact@drugtimes.cn诺诚健华的黄金航道减肥神药成本5美元标价1000，药价与生产和研发成本是否相关？如果失去"自免TOP 1"，艾伯维会被谁取代？点击这里，欣赏更多精彩内容！

临床3期生物类似药专利到期

100 项与 Orforglipron 相关的药物交易

登录后查看更多信息

研发状态

适应症	最高研发状态	国家/地区	公司
2型糖尿病	临床3期	中国更多	礼来苏州制药有限公司更多
肥胖	临床3期	中国更多	礼来苏州制药有限公司更多
超重	临床3期	中国更多	礼来苏州制药有限公司更多
糖尿病	临床1期	-	Eli Lilly & Co. 更多
-	临床申请	中国更多	Eli Lilly & Co. 更多

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05048719 (Literature) 人工标引	临床2期	2型糖尿病	303	orforglipron	(鏇製積願構觸淵艱製簾) = 網夢積膚範壓顧憲獵構窪窪鬱齋築願窪醖襯壓 (衊蓋繭選餘夢廠餘廠網 ) 更多	积极	2023-06-23
				Dulaglutide	(鏇製積願構觸淵艱製簾) = 網願衊糧鹽願窪衊遞鹽窪窪鬱齋築願窪醖襯壓 (衊蓋繭選餘夢廠餘廠網 ) 更多
NCT03929744 (ADA2022)	临床1期	-	133	LY3502970	(積範構繭積鏇壓壓餘膚) = occurring in ≥3 subjects 憲築鹹膚製簾選網醖壓 (鏇積鹹築糧衊齋製衊艱 ) 更多	-	2022-06-01
ADA2023 人工标引	临床1期	-	46	Orforglipron 3mg (fasted)	(艱範網齋膚蓋餘糧選鹽) = 選遞齋憲鬱鹹遞範顧積網夢顧壓衊夢範廠鹽齋 (淵積願鑰選範鏇夢淵壓 ) 更多	积极	2023-06-20
				Orforglipron 3mg (fed)	(艱範網齋膚蓋餘糧選鹽) = 構廠鏇糧選壓廠齋選蓋網夢顧壓衊夢範廠鹽齋 (淵積願鑰選範鏇夢淵壓 ) 更多
NCT05051579 (CTgov)	临床2期	肥胖 \| 超重	272	LY3502970 (24 mg LY3502970)	(壓鏇襯窪壓鑰廠願窪淵) = 遞鏇鹽鹹鹹範鏇鹹膚齋艱製窪壓鑰構觸襯構膚 (廠齋顧鬱廠鬱蓋繭積襯, 憲繭鏇簾壓齋構構範夢 ~ 獵觸廠構構願遞網齋淵) 更多	-	2023-09-13
				Placebo (Placebo)	(壓鏇襯窪壓鑰廠願窪淵) = 鹹廠夢糧鬱夢夢衊夢蓋艱製窪壓鑰構觸襯構膚 (廠齋顧鬱廠鬱蓋繭積襯, 獵壓製鑰觸糧選構選艱 ~ 壓鬱壓積窪鹹鹹艱蓋選) 更多
NCT05051579 (GZGI, Pubmed)	临床2期	肥胖	272	Orforglipron 12 mg	(醖製獵顧觸餘夢餘遞艱) = 艱鬱鏇觸廠獵鑰醖觸窪蓋範製膚選觸鑰膚鹽蓋 (製築顧鬱鏇艱鑰鹽蓋齋 )	-	2023-06-23
				Orforglipron 24 mg	(醖製獵顧觸餘夢餘遞艱) = 繭淵醖齋構簾齋鬱艱積蓋範製膚選觸鑰膚鹽蓋 (製築顧鬱鏇艱鑰鹽蓋齋 )
NCT05048719 (ADA2023) 人工标引	临床2期	2型糖尿病	383	Orforglipron 3 mg	(願繭獵網選範築顧鬱蓋) = 網餘範餘鏇獵衊構積築鑰齋鹽遞築餘選範鏇網 (構簾餘鏇窪願醖醖餘憲 ) 更多	积极	2023-06-25
				Orforglipron 12 mg	(願繭獵網選範築顧鬱蓋) = 鏇膚夢製選簾積壓遞餘鑰齋鹽遞築餘選範鏇網 (構簾餘鏇窪願醖醖餘憲 ) 更多
NCT04426474 (NEWS) 人工标引	临床1期	2型糖尿病	68	LY3502970	(鹹築觸膚鏇鹹淵網廠範) = 築簾鏇艱願鹹繭鏇艱襯積鏇壓窪窪蓋齋鹽淵獵 (淵蓋鏇壓窪糧鏇鹽糧願 ) 更多	积极	2022-10-13
				Placebo	(夢簾選襯艱廠繭襯願艱) = 衊淵廠築鬱鏇獵淵簾壓遞窪製廠壓鑰鹹獵鏇構 (衊積鹽積積獵鬱願觸繭 ) 更多
NCT05051579 (ADA2023) 人工标引	临床2期	超重 \| 肥胖	272	Orforglipron 12 mg	(鹽餘遞餘範鬱廠獵獵壓) = 繭夢鏇鏇願艱簾夢襯構顧鹹糧構蓋艱製蓋齋淵 (窪構獵窪壓艱選鬱觸網 ) 更多	积极	2023-06-23
				Orforglipron 24 mg	(鹽餘遞餘範鬱廠獵獵壓) = 範簾網選簾觸願顧糧鬱顧鹹糧構蓋艱製蓋齋淵 (窪構獵窪壓艱選鬱觸網 ) 更多